Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Express Scripts
Dow
AstraZeneca
Johnson and Johnson

Last Updated: January 27, 2023

Details for Patent: 6,696,481


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 6,696,481 protect, and when does it expire?

Patent 6,696,481 protects PRESTALIA and is included in one NDA.

This patent has forty-five patent family members in thirty-seven countries.

Summary for Patent: 6,696,481
Title: Salt of perindopril and pharmaceutical compositions containing it
Abstract:The present invention relates to a new salt of perindopril and to pharmaceutical compositions containing it, and Medicaments for treatment of hypertension and heart failure.
Inventor(s): Damien; Gerard (Orleans, FR), Lefoulon; Fran.cedilla.ois (Orleans, FR), Marchand; Bernard (Verneuil sur Seine, FR)
Assignee: Les Laboratoires Servier (Neuilly-sur-Seine, FR)
Application Number:10/371,865
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,696,481
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form; Use;

Drugs Protected by US Patent 6,696,481

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Adhera PRESTALIA amlodipine besylate; perindopril arginine TABLET;ORAL 205003-001 Jan 21, 2015 RX Yes No See Plans and Pricing See Plans and Pricing Y Y TREATMENT OF HYPERTENSION See Plans and Pricing
Adhera PRESTALIA amlodipine besylate; perindopril arginine TABLET;ORAL 205003-002 Jan 21, 2015 RX Yes No See Plans and Pricing See Plans and Pricing Y Y TREATMENT OF HYPERTENSION See Plans and Pricing
Adhera PRESTALIA amlodipine besylate; perindopril arginine TABLET;ORAL 205003-003 Jan 21, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y TREATMENT OF HYPERTENSION See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,696,481

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1787 See Plans and Pricing
Argentina 039428 See Plans and Pricing
Austria 271036 See Plans and Pricing
Australia 2003200700 See Plans and Pricing
Australia 2003222921 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Johnson and Johnson
Baxter
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.